Results

1–5 of 5 results for BCVA

BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)
Michael A. Singer, MD
Annual Meeting Talks
2024
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Early Fluid-Free Status & Long-Term BCVA Outcomes With Anti-VEGF Treatment in nAMD: Post Hoc Analysis of Pooled Data From HAWK & HARRIER Studies
Chirag D. Jhaveri, MD, FASRS
On Demand Cases, Courses, and Papers
2020
Best Corrected Visual Acuity (BCVA) and Central Macular Thickness (MAT) Outcomes After Fluocinolone Acetonide Intravitreal Implant Injection
Dana M. Deupree, MD
Annual Meeting Talks
2018